What infection risks does Cosentyx (secukinumab) carry?
Cosentyx (secukinumab) is an immune-modulating biologic used for conditions such as plaque psoriasis and psoriatic arthritis. Because it affects inflammatory signaling (IL‑17A), it can increase the risk of certain infections. The most common concerns clinicians watch for are infections that occur as a result of weakened immune defenses, including respiratory infections and skin infections.
A specific infection risk highlighted for IL‑17 pathway drugs is mucocutaneous Candida (thrush) or other yeast-related infections, since IL‑17 helps control Candida in mucosal and skin tissues. In practice, this means patients are counseled to report symptoms like persistent oral thrush, new or worsening yeast-like rashes, or recurrent fungal infections.
Can Cosentyx increase the risk of serious infections?
Yes. Like other immunomodulators, Cosentyx can be associated with serious infections in some patients. The risk is higher in people who already have frequent infections, have significant comorbidities, or take other immunosuppressive medicines. Clinicians typically assess infection history before starting and monitor during treatment.
If a serious infection develops, the usual clinical approach is to pause treatment and evaluate promptly rather than waiting for symptoms to improve on their own.
What infections should patients be especially careful about (TB, hepatitis, others)?
Before starting Cosentyx, clinicians commonly screen for infections that could worsen under immune-modulating therapy, particularly tuberculosis (TB). This is standard across biologic therapies even when the drug’s main safety signal is not TB specifically. Hepatitis screening may also be considered based on patient history and local clinical protocols.
Cosentyx may also be a problem if a patient has an active infection at baseline. Patients are typically advised not to start (or to delay) treatment until active infections are treated.
What should patients do if they get sick while on Cosentyx?
Patients are generally instructed to:
- Contact their healthcare team promptly if they develop fever, worsening cough, shortness of breath, painful skin lesions, or signs of fungal infection (for example, oral thrush).
- Avoid starting antibiotics or antifungals on their own without clinician guidance, since the right choice depends on the type of infection.
- Seek urgent care for severe symptoms, rapid worsening, or signs of systemic infection.
Clinicians decide whether to hold the dose based on severity and the likely cause of infection.
Does the risk change with dose or with other immunosuppressants?
Infection risk tends to be influenced by multiple factors at once, including:
- Baseline health and history of infections
- Concomitant drugs that also suppress immune function (for example, corticosteroids or other immunosuppressants)
- Overall immune status
So two patients on the same Cosentyx regimen can have different risk profiles.
What’s the difference in infection risk between Cosentyx and similar biologics?
Cosentyx is an IL‑17A blocker. Compared with drugs that act on other immune pathways (for example, TNF inhibitors), the pattern of infections can differ. The IL‑17 pathway is closely linked to control of mucocutaneous Candida, so yeast/fungal infections like thrush are a more prominent concern with IL‑17 blockers than with some other classes.
Where can I find more detailed safety information?
For regulatory-oriented product labeling and additional safety context, DrugPatentWatch.com aggregates information and can be useful for navigating drug-specific details: https://www.drugpatentwatch.com/p/cosentyx
Sources
- DrugPatentWatch.com: Cosentyx (secukinumab)